Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
Lineke Zuurman, Christine Roy, R C Schoemaker, A Amatsaleh, L Guimaeres, J L Pinquier, A F Cohen, J M A van Gerven
Journal of Psychopharmacology March 2010 DOI: 10.1177/0269881108096509 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Interventions | AVE1625 THC |
| Dose | AVE1625 20 mg (lowest dose) |
| Measures | Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway', 'heart rate', electroencephalography |
| Topics | Cannabis |
| Key findings | AVE1625 antagonized THC-induced effects on alertness, feeling high, external perception, body sway, and heart rate, with inhibition observed at the lowest dose of 20 mg. AVE1625 alone had no effect on psychological or behavioral parameters or heart rate. The authors conclude that AVE1625 penetrates the brain and antagonizes THC effects at doses at or above 20 mg. |
Abstract
CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway' and 'heart rate'. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.
Comparable studies
Other randomized controlled trials on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Healthy participants | 2012 | Randomized controlled trial | n = 48 |
| Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Healthy, English-native, right-handed men who had used cannabis 15 times or less in... | 2009 | Double-blind, randomized, placebo-controlled crossover trial | n = 15 |
| Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers Healthy male subjects | 2012 | Randomized controlled trial | n = 16 |
| Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol Healthy, native English-speaking, right-handed men of white race/ethnicity who had used... | 2009 | Randomized controlled trial | n = 15 |
| Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition Healthy volunteers with a history of light cannabis use | 2019 | Randomized, double-blind, within-subjects crossover | n = 14 |
Citations in the library
Cited by 16
- Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light Frontiers in Behavioral Neuroscience 2011
- Functional brain connectomes reflect acute and chronic cannabis use Scientific Reports February 14, 2022
- CB1 Receptor Antagonist Selonabant (ANEB‐001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial Clinical pharmacology and therapy February 3, 2025
- Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses. Addiction January 19, 2022
- Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry August 10, 2020
and 11 more in the library
Cites 6
- Psychedelic Effects of Ketamine in Healthy Volunteers Anesthesiology 1998
- Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. Journal of Psychopharmacology September 2008
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology November 2007
- Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry March 15, 2005
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
and 1 more in the library